孕妇糖耐量异常与皮下特布他林泵
Maternal glucose intolerance and the subcutaneous terbutaline pump.
作者信息
Lindenbaum C, Ludmir J, Teplick F B, Cohen A W, Samuels P
机构信息
Department of Obstetrics and Gynecology, University of Pennsylvania Medical Center, Philadelphia 19104.
出版信息
Am J Obstet Gynecol. 1992 Mar;166(3):925-8. doi: 10.1016/0002-9378(92)91364-g.
OBJECTIVE
Our hypothesis was that use of the subcutaneous terbutaline pump does not affect maternal glucose tolerance.
STUDY DESIGN
With the 1-hour glucose tolerance test, we examined the incidence of glucose intolerance in 37 patients using the pump compared with that of 54 patients receiving oral terbutaline and 634 control subjects without risk factors for gestational diabetes. The frequency of gestational diabetes and the need for insulin to maintain glycemic control were subjected to chi 2 analysis.
RESULTS
The incidence of gestational diabetes was 6% in the control subjects, 5% in patients using the pump (p = 0.8), and 11% in those on the oral therapy regimen (p = 0.4). A total of 8% of controls who had gestational diabetes required both insulin and diet, compared with 100% using the pump (p less than 0.01) and 50% on the oral terbutaline regimen (p = 0.03).
CONCLUSION
The incidence of gestational diabetes is not increased in patients receiving terbutaline via the subcutaneous pump. The use of terbutaline by any route significantly increases the need for insulin to achieve glycemic control.
目的
我们的假设是皮下使用特布他林泵不会影响母体糖耐量。
研究设计
通过1小时糖耐量试验，我们检查了37例使用该泵的患者、54例接受口服特布他林的患者以及634例无妊娠期糖尿病危险因素的对照受试者的糖耐量异常发生率。对妊娠期糖尿病的发生率和维持血糖控制所需胰岛素的情况进行卡方分析。
结果
对照受试者中妊娠期糖尿病的发生率为6%，使用泵的患者为5%（p = 0.8），口服治疗方案的患者为11%（p = 0.4）。患有妊娠期糖尿病的对照者中，共有8%需要胰岛素和饮食治疗，相比之下，使用泵的患者为100%（p < 0.01），口服特布他林方案的患者为50%（p = 0.03）。
结论
通过皮下泵接受特布他林治疗的患者中妊娠期糖尿病的发生率并未增加。通过任何途径使用特布他林都会显著增加实现血糖控制所需胰岛素的使用量。
Zotero 插件